Glucophage is the oldest and most widely used oral hypoglycemic drug. It is recommended as the first-line medication for the treatment of patients with type II diabetes by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). It works 1.by inhibiting gluconeogenesis and glycogenolysis to decrease glucose production by the liver; 2. by storing in muscle tissue and through increasing the insulin sensitivity of body tissues to improve glucose intake and utilization in peripheral tissues; 3. by delaying intestinal glucose absorption to not only lower blood sugar level but also favor lipid metabolism, and decrease total cholesterol, low density lipoprotein (LDL) cholesterol and triglycerides as well.

The use of Glucophage alone does not increase weight, and the risk of hypoglycemia is relatively low. Research has suggested that it has a good therapeutic effect on diabetes complications and related diseases, such as diabetic cardiovascular complications and polycystic ovary syndrome (PCOS).

As cancer cells rely heavily on glucose as a source of energy, Glucophage may also inhibit the growth of cancer cells and prevent the deterioration of cancer when it is used to reduce blood sugar and insulin. As a result, recent epidemiological studies, clinical observations and in vivo and in vitro studies have revealed that Glucophage may have a favorable effect on the occurrence and prognosis of certain malignant tumors, such as liver cancer, pancreatic cancer, colorectal cancer, breast cancer, prostate cancer, lung cancer and ovarian cancer.

The following experiment was performed by Mr. Yuan Lin, the first successfully-evolved and transformed New Human Line, who utilized the Absolutely Constant Energy Source (ACES) and the new biological engineering techniques to activate Glucophage to increase its concentration without any change in its molecular weight, structural formula, and conformation, at 25℃, 1.0 atm, and pH 7.0, in a confined and isolated space, and with no contact with catalysts, biologically active substances, chemical substances, and physical action forces.

From the experiment results, we can see a significant difference (p = 0.043) in the concentration between the control groups and the samples treated with the ACES by Mr. Yuan Lin. It can prove that Mr. Yuan Lin, the New Human Line, can utilize the Absolutely Constant Energy Source and the new biological engineering techniques to directly alter the concentration of Glucophage to increase its concentration, thereby affecting the metabolism and biochemical reactions in the body.

References:

1. Davies ,M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G.,…Buse, J. B. (2018). Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Retrieved from http://diabetologia-journal.org/wp-content/uploads/2018/09/EASD-ADA.pdf
2. Zi, F., Zi, H., Li, Y., He, J., Shi, Q., & Cai, Z. (2018, January). Metformin and cancer: An existing drug for cancer prevention and therapy. Oncol Lett.,15(1), 683–690. Published online 2017 Nov 14. doi: 10.3892/ol.2017.7412